Can a targeted antibody boost chemotherapy against a rare leukemia?
NCT ID NCT03264131
First seen Jul 29, 2026 · Last updated Jul 30, 2026 · Updated 1 time
Summary
This study tests whether adding a targeted drug called brentuximab vedotin to standard chemotherapy can help people with adult T-cell leukemia/lymphoma (ATLL), a rare and aggressive blood cancer. The combination, known as BV-CHEP, aims to improve response rates by targeting a marker called CD30 found on cancer cells. The trial enrolls adults with ATLL and measures how many achieve complete remission after treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- a combination of brentuximab vedotin and chemotherapy drugs (cyclophosphamide, doxorubicin, etoposide, and prednisone)
- What this could lead to
- If it works, this could point toward a more effective treatment for a rare and hard-to-treat cancer that currently has no standard therapy.
- What could go wrong
- This is a small pilot study, so results may not apply to all patients. The combination includes strong chemotherapy drugs, which can cause significant side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADULT T-CELL LEUKEMIA/LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Beth Israel Deaconess Medical Center (BIDMC)
Boston, Massachusetts, 02215, United States
-
Boston Medical Center
Boston, Massachusetts, 02118, United States
-
Lineberger Comprehensive Cancer Center at the University of North Carolina at Chapel Hill
Chapel Hill, North Carolina, 27599, United States
-
South Broward/Memorial Healthcare System
Hollywood, Florida, 33021, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could muscle loss predict blood cancer outcomes?
- Can a Low-Dose antifungal shield vulnerable patients from deadly fungal infections?
- Can engineered immune cells tackle brain lymphoma?
- Talking about the end: could guided conversations reduce futile cancer treatments?
- A simple blood test may reveal hidden infertility risk in young cancer survivors
- Can a targeted pill boost Chemotherapy's punch against lymphoma?